Background: The vascular endothelial growth factor (VEGF) plays a central role in angiogenesis and immunosuppressive cascades inherent to tumor development. Success of drugs targeting this growth factor and their receptors signaling cascade built upon these facts. Such passive targeting of VEGF/VEGFR pathway had two major caveats: non-manageable side effects and the induction of resistance phenomena. To overcome some of these problems we design an active immunization approach based on the use of a functionally deficient VEGF 121 isoform as antigen. Herein we present preclinical and clinical development data of HeberSaVax vaccine (formerly known as CIGB-247). Methods: Safety, antitumoral and immunological effects of HeberSaVax administration were analyzed in mouse, rats, rabbits, non-human primates and in two Phase I clinical trials. Formulations containing the adjuvants VSSP (Very Small Size Particles from Neisseria Meningitides) or Alum phosphate were used. Vaccine was administered once a week (VSSP) or bi-weekly (Alum Phosphate) for 8 weeks. Immune response was evaluated using direct and indirect ELISA methods and IFN-gamma ELISPOT. Results: HeberSaVax administration inhibits implantation and growth of tumors and metastases favoring a significant increase in animals' survival. In mice, rats, rabbits and on non-human primates the vaccine administration result in non-toxic induction of sustained antibody titers that specifically neutralized VEGF binding to VEGF receptors. Immunizations also induce VEGF specific cell mediated cytotoxicity. A total of 80 patients were included in the phase I/Ib clinical trials. Results indicated: a good safety profile that allows combining the vaccine with the existing arsenal for cancer therapy; the induction of specific humoral and cellular responses despite the advance stage of patient's tumors and; an unexpected long term immune responses after 4 years of continuous treatment. Background: Virus-based vaccines and appropriate costimulation enhance potent antigen-specific T cell immunity against cancer. In the present study we exploit both innate and adaptive immune responses triggered by a novel recombinant modified vaccinia virus Ankara (rMVA) encoding costimulatory CD40L against solid tumors in combination regimes to overcome tumor-induced resistance to immunotherapy. Methods: Mice bearing tumors > 50 mm 3 in volume were immunized intravenously and treated with monoclonal antibodies when indicated. Immune infiltrates were analyzed by flow cytometry. When indicated, immune populations were isolated to perform functional assays. Results: Therapeutic treatment with rMVA-CD40L resulted in strong antitumor effects in unrelated established tumor models. Tumor infiltration was composed of non-exhausted, antigen-specific CD8 þ T cells with proliferative capacity after rMVA-CD40L immunization. Strikingly, this antitumor effect was not entirely dependent on crosspresenting CD8a þ DC -induced CD8 þ T cell expansion. Indeed, rMVA-CD40L-induced tumor control did not depend on cytosolic DNA sensor STING. Interestingly, rMVA-CD40L induced strong NK cell activation and thereby potent Antibody Dependent Cell Cytotoxicity (ADCC) against Tumor-Associated Antigen (TAA) targeting antibodies. Hence, the combination of TAA targeting antibodies and rMVA-CD40L resulted in increased therapeutic antitumor efficacy. Conclusions: We describe a novel and translationally relevant therapeutic synergy between viral vaccination and CD40L costimulation. We connect CD40 ligation to crosspresenting CD8a þ DC -mediated expansion of non-exhausted CD8 þ T cells in the tumor microenvironment. Taking advantage from intrinsic MVA-induced NK cell activation and further improved NK cell function by CD40 ligation, we show strengthened antitumor immune responses when both rMVA-CD40L-induced innate and adaptive immune mechanisms are exploited by combining immunotherapeutic regimes. This finding has a direct potential impact in clinical trials where TAA targeting antibodies are currently under evaluation. Legal entity responsible for the study: Bavarian Nordic GmbH The impact of CHVI on the feasibility and efficacy for patients with HCC in Phase I trials (P-Is) has not been reported or elucidated in Western countries. Methods: We retrospectively analyzed the characteristics and outcomes of HCC patients participating in P-Is, with emphasis on CHVI. Patients testing positive for antihepatitis C virus (HCV) antibody or hepatitis B virus surface antigen (HBsAg) were diagnosed with CHVI. Results: Eighty-five patients were enrolled in P-Is at our center. There were no significant differences in the clinical and laboratory variables, including the liver function test results, between the 46 (54%) CHVI-positive and 39 (46%) CHVI-negative patients in this study. The median time to treatment failure (TTF) and overall survivals (OS) from enrollment of the P-I were 60 days (95% confidence interval [CI]: 51-85) and 412 days (95% CI: 267-478), respectively. There is no significant difference between positive and negative for hepatitis virus in the best response based on the RECIST. The frequency of abnormal liver function test (LFT) adverse events (grade 3) was significantly different among CHVIpositive and -negative patients. No patient discontinued P-I treatment secondary to abnormal LFT results or developed reactivation of hepatitis virus, and no treatment-related mortality was observed. Multivariate analysis revealed that the number of prior systemic treatments significantly contributed to poor TTF (2; HR: 2.1, 95% CI: 1.3-3.6, P ¼ 0.004) and that poor Eastern Cooperative Oncology Group Performance Status significantly contributed to poor OS (1; HR: 1.9, 95% CI: 1.0-3.4, P ¼ 0.04). Conclusions: CHVI did not independently predict TTF and OS. Abnormal LFT adverse events could be related to CHVI but did not lead to discontinuation of P-I treatment. Thus, patients advanced HCC with CHVI can be enrolled in the P-Is. Legal entity responsible for the study: N/A Funding: Has not received any funding Disclosure: All authors have declared no conflicts of interest. 
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active PI3K pathway, and have direct effect on prognosis of breast cancer. Although many small molecules are used in clinic to target the PI3K pathway, only minority of breast cancer patients respond to these drugs. This study identified the role of a deubiquitinating enzyme, USP10 in the regulation of PI3K pathway in breast cancer. Methods: A genome wide RNAi screen targeting all known deubiquitinating enzymes was performed and level of phospho-AKT was assessed by western blotting. Significant hits of the screen were validated and mechanism of action in PTEN-mediated regulation of PI3K pathway and resistance to PI3K inhibitors in breast cancer has been investigated.
Results:
We identified USP10 as a critical regulator of PI3K pathway. MAGI1 has been recently identified as PTEN interacting protein, and along with MEK1 functions to promote PTEN recruitment to the plasma membrane. We found USP10 as a part of complex between MEK1, MAGI1 and PTEN. Functionally, we demonstrated that USP10 stabilizes ITCH which is an E3 ligase for MEK1 resulting in degradation of MEK1 and decreased PTEN plasma membrane localization. We showed that downregulation of USP10 decreases activation of AKT, and results in decreased colony forming ability of breast cancer cells. Furthermore, expression analysis of USP10 revealed significantly higher levels of USP10 in breast cancer patients and its expression was correlated with the tumor progression and poorer overall survival in the breast cancer patients. Interestingly, we showed the upregulation of USP10 protein level in PI3K inhibitor resistant breast cancer cells as compared to their parental control and further depletion of USP10 resensitized these cells to PI3K inhibitors. In addition, positive correlation between USP10 and PTEN protein levels was observed in the PDX model of breast cancer patients who progressed after receiving PI3K inhibitor. Conclusions: Overall, our results identify overexpression of USP10 as a potential mechanism for loss of PTEN functionality and PI3K pathway in breast cancer patients, and its possible involvement in resistance to PI3K inhibitors. Legal entity responsible for the study: National University of Singapore Funding: National University of Singapore Disclosure: All authors have declared no conflicts of interest. Methods: On a tissue microarray (TMA) with bone marrow biopsies from 119 MDS patients, 40 AML pts, and 11 normal controls, we established immunohistochemistry (IHC) for NEDD8, NAE1 and UBE2M. Semi-quantitative analysis was done according to Remmele-Stegner immunoreactive score (IRS) (0 to 12 points). Clinical follow-up was available for 116 pts. Results: Of 96 evaluable MDS pts, 46 (39.7%) showed an abnormal karyotype. Ten patients who received disease-modifying treatment prior to biopsy were excluded from survival analysis. On IHC, 100% of 40 AMLs and 11 normal controls were clearly positive (IRS>4) for all three NEDDylation pathway proteins. MDS patients showed a different pattern. While NEDD 8 was positive in the majority (60.6%), NAE1 and UBE2M were expressed in only 30.8% and 29.4%, respectively. For each protein, expression was not correlated with MDS type (WHO 2016), IPSS-R risk group, overall survival or AML transformation. Patients with strong expression of all three proteins survived longer (51 vs. 26 months), but the difference did not reach statistical significance (p ¼ 0.10). Low expression of NAE1 and UBE2M significantly correlated with the presence of karyotype anomalies (p ¼ 0.01 and p ¼ 0.02, respectively). Conclusions: In contrast to AML, expression of NEDD8 conjugation pathway proteins was low in a substantial proportion of MDS patients. The significant association between low or absent expression of NAE1 and UBE2M, and the presence of karyotype anomalies, suggests that low NEDDylation pathway activity may contribute to chromosomal instability. Nevertheless, since NEDD8 increases DNMT3b-dependent DNA methylation, NEDDylation pathway inhibition may be useful to augment treatment with hypomethylating drugs or counteract resistance to this therapy. Legal entity responsible for the study: Universit€ atsklinikum Düsseldorf Funding: Takeda Pharmaceutical Company Disclosure: F. Majidi, N. Gattermann: The current research project is funded by Takeda Pharmaceutical Company. All other authors have declared no conflicts of interest. Lu-PSMA (a theranostic for treatment of prostate cancer). Data has previously been presented showing NOX66 400mg to be well tolerated as monotherapy and in combination with carboplatin. Here we present data for patients receiving 800mg NOX66. Methods: Nineteen patients with end stage metastatic cancer (breast, lung, prostate and ovarian) were enrolled between March and September 2017 across four centres in Georgia. Patients were allocated to one of three treatment cohorts: Cohort 1 (n ¼ 8) receives 400mg NOX66 daily, Cohort 2 (n ¼ 8) and 3 (n ¼ 3) receive 800mg daily. Each patient receives NOX66 for up to seven months in the following regimen: -Part A: Monotherapy -14 consecutive days of NOX66 treatment followed by 7 Days rest (Cohorts 1 and 2 only); -Part B: Carboplatin AUC4 -3 x 28 Day cycles; NOX66 Days 1-7, Carboplatin Day 2; -Part C: Carboplatin AUC6 -3 x 28 Day cycles; NOX66 Days 1-7, Carboplatin Day 2. Efficacy is measured by change in from baseline in radiological scans (using RECIST v 1.0 criteria) at End of Cycle 3 and Cycle 6. Adverse Events are monitored from enrolment until 30 days post Cycle 6. Results: Data presented is for Cohort 2, Part A and B (Cohort 1 presented at ESMO2017). Of the 8 patients treated with 800mg NOX66, 7 completed monotherapy (one withdrawal prior to dosing). No AEs related to NOX66 were reported. Following three cycles of combination with carboplatin AUC4, 1 patient reported partial response, 4 stable disease and 1 disease progression. No AEs related to NOX66 have been reported. Conclusions: NOX66 at 800mg is well tolerated as monotherapy and in combination with low dose carboplatin. Efficacy signals support further investigation of NOX66 in combination with standard chemotherapy. Clinical trial identification: Protocol NOX66-001A; NCT02941523 Legal entity responsible for the study: Noxopharm Funding: Noxopharm Disclosure: G. Kelly: Employee, board member and significant shareholder of the sponsor company, Noxopharm Limited. I. Minns: Employee of the sponsor company, Noxopharm Limited.
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